文 | 张阳阳 2月5日，A股三大指数集体下跌，截至收盘，上证指数跌0.64%，深证成指跌1.44%，创业板指跌 1.55%；北证50跌2.03%。沪深两市成交额约21762.2亿元，较前一个交易日缩量约3047.52亿元。 山西板块今日整体表现疲软，指数下跌1.52%，成交额为167.59亿元，显示市场活跃度偏低且情绪偏谨 慎。 个股涨跌层面，山西板块41只股票，8只上涨、33只下跌，下跌个股占比超八成。 上涨个股中，仟源医药涨5.62%；锦波生物涨3.18%；科新发展、狮头股份涨逾1%；广誉远、大秦铁 路、山西证券和派林生物涨幅均不到1%。 下跌个股中，北方铜业跌达7.25%；安泰集团、山煤国际、华阳股份等6只个股跌逾4%；山西焦煤、太 钢不锈跌超3%；兰花科创、科达自控、美锦能源等6只个股跌超2%；蓝焰控股、潞化科技、跨境通等 11只个股跌逾1%；壶化股份、晋控煤业、华翔股份等7只个股跌幅较温和，均在1%以下。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000403 证券简称：派林生物 公告编号：2026-002 药物名称：人凝血因子IX 剂型：注射剂 规格：500IU/瓶，复溶后10ml 申请事项：境内生产药品注册上市许可 申请人：广东双林生物制药有限公司 派斯双林生物制药股份有限公司 关于全资子公司获得药品注册上市许可受理通知书的公告 本公司及董事会全体成员保证信息披露的内容的真实、准确和完整，没有虚假记载、误导性陈述或者重 大遗漏。 近日，派斯双林生物制药股份有限公司（以下简称"公司"）之全资子公司广东双林生物制药有限公司 （以下简称"广东双林"）收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通 知书》（受理号：XCSS2600002），现将有关情况公告如下： 一、药品基本情况 五、风险提示 公司已获得人凝血因子IX药品注册上市许可《受理通知书》，具体审批完成时间尚不确定，公司将按 照国家有关规定，积极推进上述研发项目，将根据后续进展情况及时履行信息披露义务，敬请广大投资 者注意投资风险。 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以受理。 ...

Group 1 - Sileck's subsidiary received a project designation letter from a South Korean battery customer, expected to supply approximately 360 million cylindrical battery shells from 2027 to 2031 [1] - Fuguang Co.'s major shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 481.68 million shares [2] - Beixin Road and Bridge's consortium won a contract for a project worth 1.145 billion yuan, with two segments valued at 223.1 million yuan and 921.5 million yuan respectively [3] Group 2 - Jianyou Co.'s subsidiary received FDA approval for sodium selenite injection, aimed at providing selenium for parenteral nutrition in adults and pediatric patients [4] - China Galaxy received approval to publicly issue subordinated bonds totaling up to 20 billion yuan [6] - Changjiang Electric Power announced a cash dividend of 0.21 yuan per share, totaling 5.138 billion yuan [7] Group 3 - Zhongjin Company received approval to publicly issue corporate bonds totaling up to 20 billion yuan [8] - Daon Co. received a decision from the State Administration for Market Regulation not to conduct further antitrust review on its acquisition of Ningbo Aisikai Synthetic Rubber Co. [10] - Palm Co. won a project worth approximately 228 million yuan, which is expected to account for 7.44% of its audited revenue for 2024 [11] Group 4 - Kang En Bei's subsidiary received approval for clinical trials of TFA003 tablets for diabetic nephropathy [13] - Xinmai Medical's subsidiary obtained a medical device registration certificate for polyvinyl alcohol embolization microspheres [14] - Guangsheng Tang's innovative hepatitis B drug completed the enrollment of 578 participants in its Phase III clinical trial [15] Group 5 - Pianzaihuang's controlling shareholder received a loan commitment for up to 450 million yuan to support share buybacks [16] - Liya De plans to invest up to 100 million yuan in an industry fund focused on commercial aerospace [17] - Zhongwen Online plans to collaborate with Tencent on animation micro-short drama licensing, with an expected cooperation amount of 23.2 million yuan [19] Group 6 - Yungsheng Technology is planning to acquire control of Fengrui Fluorine Industry, with its stock continuing to be suspended [22] - Yinbang Co. received a sales order from HOLTEC ASIA for approximately 280 million yuan, expected to positively impact its operations in 2026 and 2027 [23] - Pailin Bio's subsidiary received a drug registration acceptance notice for human coagulation factor IX [24] Group 7 - Dao Dao Quan plans to apply for soybean oil delivery warehouse qualifications from the Dalian Commodity Exchange [25] - Qizheng Tibetan Medicine's subsidiary received a registration certificate for a traditional Chinese medicine product in Macau [26] - Vili Medical received EU MDR certification for multiple products [27][28] Group 8 - CITIC Bank plans to increase its investment in its wholly-owned subsidiary by 2 billion yuan [29] - Hayao Co. received approval for the consistency evaluation of its injectable drugs [30] - Zhifei Biological's freeze-dried varicella vaccine clinical trial received approval [31] Group 9 - Huibo Pu signed a contract worth 225 million USD for the Naft Khana oilfield recovery project [32] - Zhonggu Logistics plans to invest in the construction of two 6000 TEU container ships, with a total contract amount not exceeding 1.16 billion yuan [33] - Chongqing Beer reported a 10.43% increase in net profit for 2025, with revenue of 14.722 billion yuan [34] Group 10 - Huanxu Electronics reported a 12.16% increase in net profit for 2025, with revenue of 59.195 billion yuan [35] - Chengzhi Co.'s subsidiary successfully completed trial production of a high molecular weight polyethylene project [36] - Guangyang Co. signed a strategic cooperation agreement with Shenzhen Xuanchuang and Huangshan Guangyang [37]

Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the approval notice for the marketing registration of human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approved drug, human coagulation factor IX, is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug is expected to significantly increase the levels of human coagulation factor IX in the blood, thereby achieving the goal of preventing and treating bleeding [1]

派林生物（000403）(000403.SZ)公告，公司全资子公司广东双林生物制药有限公司(称"广东双林")收到 国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。 ...

智通财经APP讯，派林生物(000403.SZ)公告，公司全资子公司广东双林生物制药有限公司(称"广东双 林")收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。 ...

格隆汇2月4日丨派林生物(000403.SZ)公布，全资子公司广东双林生物制药有限公司（简称"广东双林"） 收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。人凝血因子IX 适应症：对于治疗先天性人凝血因子Ⅸ缺失的乙型血友病患者或因其它原因引起的人凝血因子Ⅸ含量低 下的患者，可显著提升其血液中人凝血因子Ⅸ的水平，从而达到预防和治疗出血的目的。乙型血友病属 罕见病，长期临床用药紧缺，现有治疗用药活性回收率待提升。公司长期以患者为中心，将致力于研发 高回收率的血源性药品。 ...

药物名称：人凝血因子 IX 剂型：注射剂 证券代码：000403 证券简称：派林生物 公告编号：2026-002 派斯双林生物制药股份有限公司 关于全资子公司获得药品注册上市许可受理通知书的公告 本公司及董事会全体成员保证信息披露的内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 近日，派斯双林生物制药股份有限公司（以下简称"公司"）之全资子公司广东双 林生物制药有限公司（以下简称"广东双林"）收到国家药品监督管理局核准签发的人 凝血因子IX药品注册上市许可《受理通知书》（受理号：XCSS2600002），现将有关情 况公告如下： 一、药品基本情况 公司获得人凝血因子 IX 药品注册上市许可《受理通知书》，对公司当期业绩不会产 生影响，长期将进一步丰富公司产品线，有利于优化公司产品结构，有利于提升公司原 料血浆综合利用率和盈利能力，进一步提升公司的核心竞争力。 规格：500IU/瓶，复溶后 10ml 申请事项：境内生产药品注册上市许可 申请人：广东双林生物制药有限公司 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定 予以受理。 二、药品研发及相关情况 人凝血因子IX适 ...

派林生物公告，近日，全资子公司广东双林生物制药有限公司收到国家药品监督管理局核准签发的人凝 血因子IX药品注册上市许可《受理通知书》（受理号：XCSS2600002）。人凝血因子IX适应症：对于 治疗先天性人凝血因子Ⅸ缺失的乙型血友病患者或因其它原因引起的人凝血因子Ⅸ含量低下的患者，可 显著提升其血液中人凝血因子Ⅸ的水平，从而达到预防和治疗出血的目的。 ...

（文章来源：证券日报） 证券日报网讯 2月3日，派林生物发布公告称，近日，公司之全资子公司广东双林生物制药有限公司收 到国家药品监督管理局核准签发的静注人免疫球蛋白药品补充申请《受理通知书》。 ...